Dr. Clete Barrick

Straight Shot with Dr. Clete Barrick

Health EN ↓ 6 episodes

 Straight Shot is the GLP-1 podcast for patients who want the real information, not the watered-down version. Dr. Clete Barrick is dual board-certified in internal medicine and obesity medicine, has treated thousands of patients on GLP-1 medications, and has personally lost over 80 pounds on tirzepatide. Each week he breaks down one focused topic: how these medications work, how to optimize your results, what your doctor isn't telling you, and what the science actually says. No guests. No fluff. No corporate script. Just the straight shot, from a doctor who lives it. New episodes weekly. Visit...

Author

Dr. Clete Barrick

Category

Health

Podcast website

www.buzzsprout.com

Latest episode

May 18, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

ECO 2026: 5 Studies That Will Change How You Use GLP-1s 18.05.2026

Twelve thousand researchers. Hundreds of presentations. Five studies that matter. Dr. Clete Barrick breaks down the most important GLP-1 research presented at the European Congress on Obesity 2026 in Istanbul, and what each finding means for patients on Ozempic, Wegovy, Mounjaro, and Zepbound right now. He covers the new higher-dose Wegovy data (7.2 mg), the maintenance dosing trial Zepbound patie...

Foundayo vs. Oral Wegovy: Which GLP-1 Pill Should You Actually Take? 03.05.2026

There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick (board-certified in internal medicine and obesity medicine) breaks down the side-by-side: the chemistry, the dosing rules, the weight loss data, the side effects, the cost, and which patient profile fits each pill. What you'll learn: - Why Foundayo (orforglipron) and oral Wegovy (sema...

The "Hidden" GLP-1 Side Effects Study: What Every Headline Got Wrong 26.04.2026

A new study in Nature Health used AI to scan over 400,000 Reddit posts from 67,000 GLP-1 users and uncovered side effects that aren't on the label. Fox News, CNN, and Medscape ran the same headline: "hidden side effects doctors are missing." Dr. Clete Barrick, board-certified in internal medicine and obesity medicine, prescribes these medications every day and takes tirzepatide hims...

Semaglutide vs. Tirzepatide: A Doctor's Honest Comparison 11.04.2026

Semaglutide or tirzepatide? Ozempic or Mounjaro? It's the most asked question in GLP-1 medicine, and Dr. Clete Barrick has prescribed both to over 5,000 patients. In this episode, he covers the real differences between single and dual agonist medications, the head-to-head SURMOUNT-5 trial results, side effect profiles (including the birth control interaction most providers miss), who actually...

How GLP-1s Actually Work (in Plain English) 07.04.2026

Your body already makes GLP-1 every time you eat. The problem? Natural GLP-1 lasts about two minutes before an enzyme destroys it. Semaglutide and tirzepatide are engineered to do the same job, just louder and longer. Dr. Clete Barrick breaks down how these medications work at three job sites: your pancreas, your stomach, and (most importantly) your brain. He explains the difference between homeos...

Episode 1: Welcome to Straight Shot 06.04.2026

Dr. Clete Barrick is dual board-certified in internal medicine and obesity medicine, has treated thousands of GLP-1 patients going on five years, and has personally lost over 80 pounds on tirzepatide. In this premiere episode of Straight Shot, he tells the full story: how a Navy physician couldn't outrun his own biology, what changed when the food noise went quiet, and why he built this show....

Listen to the Straight Shot with Dr. Clete Barrick podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.